Keppra, an antiepileptic drug, has demonstrated significant efficacy in controlling seizures. In clinical trials, it has been shown to reduce seizure frequency by at least 50% in a substantial portion of patients with partial-onset seizures, both as an add-on therapy and as monotherapy [1]. For adults with epilepsy, studies indicate that approximately 40% of patients treated with Keppra (levetiracetam) as adjunctive therapy achieved a 50% or greater reduction in seizure frequency compared to placebo [2].
How effective is Keppra for different seizure types?
Keppra is primarily indicated for the treatment of partial-onset seizures in adults and children [3]. Its effectiveness has also been studied in generalized tonic-clonic seizures, where it has shown positive results in reducing seizure occurrences. For certain types of epilepsy syndromes, such as juvenile myoclonic epilepsy, Keppra is considered a first-line treatment option due to its favorable efficacy profile [4].
What is the typical dosage and administration of Keppra?
Dosage for Keppra varies based on the patient's age, weight, and the type of seizure being treated [5]. It is typically administered orally twice a day. The initial dose for adults and adolescents aged 16 and older with partial-onset seizures is usually 500 mg twice daily. The dose can be increased to 1000 mg twice daily, and then potentially to a maximum of 1500 mg twice daily, depending on the patient's response and tolerability [5].
When does Keppra's patent exclusivity expire?
The patent exclusivity for Keppra has largely expired, allowing for the availability of generic versions. The original patent for levetiracetam expired in the United States in 2008 [6]. This expiry opened the door for generic manufacturers to produce and market their own versions of the drug, often leading to reduced prices [7].
Who are the main manufacturers of Keppra and its generics?
The original developer and marketer of Keppra was UCB Pharma [3]. Following patent expiry, numerous pharmaceutical companies now manufacture and distribute generic versions of levetiracetam. Companies such as Teva Pharmaceuticals, Mylan (now Viatris), and Apotex are among the major producers of generic levetiracetam [8].
What are the potential side effects associated with Keppra?
Common side effects reported with Keppra include somnolence, asthenia (weakness), dizziness, and behavioral abnormalities such as aggression or hostility [2][3]. Some patients may experience mood changes, irritability, and fatigue. Less common but serious side effects can occur, and patients should discuss any concerns with their healthcare provider.
How does Keppra compare to other epilepsy medications?
Keppra is often compared to other antiepileptic drugs (AEDs) in terms of efficacy, tolerability, and side effect profiles [9]. Compared to some older AEDs, Keppra is generally considered to have a more favorable tolerability profile and fewer drug-drug interactions, which can be an advantage in polytherapy regimens [4][9]. However, individual patient responses can vary significantly.
What clinical data supports Keppra's effectiveness?
Extensive clinical trials have been conducted to establish Keppra's efficacy. These studies, including pivotal Phase III trials, demonstrated statistically significant reductions in seizure frequency compared to placebo in patients with refractory epilepsy [1][2]. Long-term studies have also confirmed its sustained effectiveness and tolerability in many patients [1].
What are the risks or contraindications for using Keppra?
Keppra is contraindicated in individuals with hypersensitivity to levetiracetam or any of its ingredients [3]. Patients with certain kidney impairments may require dose adjustments [5]. While generally well-tolerated, potential risks include behavioral and psychiatric side effects, as well as the possibility of serious skin reactions [3].
What is the cost of Keppra and its generic alternatives?
The cost of Keppra can vary. Brand-name Keppra is typically more expensive than its generic counterparts. Generic levetiracetam is widely available and generally more affordable, with prices often influenced by insurance coverage, pharmacy, and dosage [7]. Information on specific pricing can be found through drug pricing websites and by consulting with pharmacies.
Sources:
[1] https://www.drugpatentwatch.com/drugs/keppra
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709387/
[3] https://www.ema.europa.eu/en/medicines/human/EPAR/keppra
[4] https://www.epilepsy.com/treatment/drug-list/keppra
[5] https://www.drugs.com/dosage/keppra.html
[6] https://www.drugpatentwatch.com/drugs/keppra/us-patents
[7] https://www.singlecare.com/drugs/keppra
[8] https://www.goodrx.com/keppra
[9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149017/